ALVR Live signaler | Maksimer profitt med Getagraph.com

KJøP 112545 min ago

@ $0.677

Utstedt: 14 feb 2024 @ 21:54

Avkastning: 19.08%

Forrige signal: feb 13 - 19:31

Forrige signal: Selg

Avkastning: 0.83 %

Live Chart Being Loaded With Signals

Commentary (2 mai 2024 @ 22:00):

Stats
Dagens volum	141 181
Gjennomsnittsvolum	594 178
Markedsverdi	92.68M
EPS	$0 ( 2024-03-20 )
Neste inntjeningsdato	( $0 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.440
ATR14	$0.00300 (0.37%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Hagen Brett R	Sell	473	Common Stock
2024-04-22	Hagen Brett R	Sell	480	Common Stock
2024-04-19	Miller Edward	Sell	626	Common Stock
2024-04-22	Miller Edward	Sell	757	Common Stock
2024-04-19	Brainard Diana	Sell	9 601	Common Stock

INSIDER POWER
83.65
Last 98 transactions
Buy: 5 809 216 \| Sell: 427 568

Volum Korrelasjon

Lang: 0.13 (neutral)

Kort: -0.21 (neutral)

Signal:(46.035) Neutral

AlloVir, Inc. Korrelasjon

10 Mest positive korrelasjoner
BCLI	0.953
CVAC	0.952
CRNC	0.951
RSLS	0.949
PYPD	0.948
LYT	0.947
IKT	0.944
TNYA	0.944
RANI	0.943
SONN	0.942

10 Mest negative korrelasjoner
EBSB	-0.952
HERA	-0.95
ISEE	-0.949
FXCO	-0.946
MTRX	-0.944
GXII	-0.943
FTPA	-0.943
NOVV	-0.943
TBSA	-0.942
HERAU	-0.94

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

AlloVir, Inc. Korrelasjon - Valuta/Råvare

0.50
( neutral )

0.56
( weak )

0.00
( neutral )

-0.53
( weak negative )

AlloVir, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-398 000 (0.00 %)
EPS:	$-1.830

FY	2023
Omsetning:	$0
Bruttogevinst:	$-398 000 (0.00 %)
EPS:	$-1.830

FY	2022
Omsetning:	$0
Bruttogevinst:	$-2.57M (0.00 %)
EPS:	$-2.20

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-6.39

Financial Reports:

No articles found.

AlloVir, Inc.

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.